Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Adam Zlotnick
Indiana University Bloomington, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Door Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Zlotnick has a new faculty start up company, Door Pharmaceuticals, that has recently been created. They will be looking at developing new antiviral drugs that target virus structural proteins. This new award is looking at virus capsid assembly and disassembly which will play a role in how a new antiviral drug could work. At the moment Door Pharmaceuticals is looking at high throughput screening to help find a promising antiviral drug.
Single-Particle Analysis of Virus Capsid Assembly and Disassembly by Resistive-Pulse Sensing
Project Narrative In this project, we are developing instrumentation and methods to determine the assembly pathways of viruses with particular emphasis placed on nucleation and intermediate formation and how antiviral assembly effectors impact these processes. Understanding virus assembly is of fundamental interest to virologists, is a focus of antiviral development, has implications for harnessing viruses for nanotechnology, and is a general model for self-assembly. Moreover, capsid assembly of Hepatitis B virus (HBV) has become an important target for antiviral development because more than 240 million people worldwide are infected with HBV, and every year 600,000 people die of HBV-related liver disease.
Filed on September 19, 2018.
Tell us what you know about Adam Zlotnick's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Adam Zlotnick”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Adam Zlotnick | Indiana University Bloomington | Conflict of Interest | Assembly Pharmaceuticals, Inc | Value cannot be readily determined |
| Adam Zlotnick | Indiana University Bloomington | Conflict of Interest | Assembly Bioscience | Value cannot be readily determined |
| Adam Zlotnick | Indiana University Bloomington | Conflict of Interest | Assembly Bioscience | $200,000 - $249,999 |
| Adam Zlotnick | Indiana University Bloomington | Conflict of Interest | Door Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.